NIOX Group (LON:NIOX) Stock Price Down 1.1% - Time to Sell?

Key Points

• NIOX Group shares fell 1.1% to GBX 56.40 on Wednesday, with volume of ~223,358 shares—about 72% below the average daily volume.
• Deutsche Bank lowered its price target from GBX 90 to GBX 86 but maintained a "Buy" rating; the analyst consensus rating is Buy with an average target of GBX 86.
• Key fundamentals: market cap £235.79 million, P/E 34.39, strong liquidity (current ratio 3.81), last quarter EPS GBX 4.03 and a net margin of 14.37%.

NIOX Group Plc (LON:NIOX - Get Free Report)'s stock price dropped 1.1% during trading on Wednesday . The stock traded as low as GBX 56 and last traded at GBX 56.40. Approximately 223,358 shares changed hands during trading, a decline of 72% from the average daily volume of 801,564 shares. The stock had previously closed at GBX 57.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft lowered their price target on shares of NIOX Group from GBX 90 to GBX 86 and set a "buy" rating for the company in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, NIOX Group has an average rating of "Buy" and an average target price of GBX 86.

NIOX Group Stock Down 1.1%

The firm's 50 day moving average is GBX 61.02 and its two-hundred day moving average is GBX 66.58. The firm has a market cap of £235.79 million, a P/E ratio of 34.39 and a beta of 0.92. The company has a current ratio of 3.81, a quick ratio of 1.94 and a debt-to-equity ratio of 1.36.

NIOX Group (LON:NIOX - Get Free Report) last released its quarterly earnings data on Tuesday, March 24th. The company reported GBX 4.03 earnings per share for the quarter. NIOX Group had a net margin of 14.37% and a return on equity of 10.14%. As a group, research analysts anticipate that NIOX Group Plc will post 1.1658256 EPS for the current fiscal year.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings. Headquartered in the UK and listed on the London Stock Exchange ticker: NIOX, the company operates internationally, serving healthcare professionals in over 50 countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.